press releases

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will participate in the 36th Annual J.P. Morgan Healthcare Conference on January 10, 2018, in San Francisco. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts. Mr. Doyle’s… Read More

The EF-14 trial is the first trial in over a decade to demonstrate statistically and clinically significant extension of overall survival of patients with newly diagnosed glioblastoma regardless of patient characteristics ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the final analysis of its phase… Read More

The EF-14 trial is the first trial in over a decade to demonstrate statistically and clinically significant extension of overall survival of patients with newly diagnosed glioblastoma regardless of patient characteristics ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the final analysis of its phase… Read More

PANOVA 3 will determine the efficacy and safety of Tumor Treating Fields in combination with nab-paclitaxel and gemcitabine as a frontline treatment for unresectable locally advanced pancreatic cancer Tumor Treating Fields in combination with nab-paclitaxel and gemcitabine more than doubled progression free survival and the one-year survival… Read More

PANOVA 3 will determine the efficacy and safety of Tumor Treating Fields in combination with nab-paclitaxel and gemcitabine as a frontline treatment for unresectable locally advanced pancreatic cancer Tumor Treating Fields in combination with nab-paclitaxel and gemcitabine more than doubled progression free survival and the one-year survival… Read More

Japan represents the largest medical device market in which Novocure has received governmental reimbursement for Optune for the treatment of newly diagnosed glioblastoma ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that the Japanese Ministry of Health, Labour and Welfare has approved the recommendation by Japan’s Central… Read More

Japan represents the largest medical device market in which Novocure has received governmental reimbursement for Optune for the treatment of newly diagnosed glioblastoma ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that the Japanese Ministry of Health, Labour and Welfare has approved the recommendation by Japan’s Central… Read More

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that it will participate in two upcoming investor conferences in December. Asaf Danziger, Novocure’s Chief Executive Officer, and Wilco Groenhuysen, Novocure’s Chief Financial Officer, will participate in a fireside chat at the Nasdaq 37th International Investor Conference on December… Read More

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that it will participate in two upcoming investor conferences in December. Asaf Danziger, Novocure’s Chief Executive Officer, and Wilco Groenhuysen, Novocure’s Chief Financial Officer, will participate in a fireside chat at the Nasdaq 37th International Investor Conference on December… Read More